ENLON-PLUS Drug Patent Profile

Which patents cover Enlon-plus, and what generic alternatives are available?

Enlon-plus is a drug marketed by Pharmobedient and is included in two NDAs.

The generic ingredient in ENLON-PLUS is atropine sulfate; edrophonium chloride. There are twenty-three drug master file entries for this compound. Additional details are available on the atropine sulfate; edrophonium chloride profile page.

Summary for ENLON-PLUS

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	16
Patent Applications:	3,904
DailyMed Link:	ENLON-PLUS at DailyMed

US Patents and Regulatory Information for ENLON-PLUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	ENLON-PLUS	atropine sulfate; edrophonium chloride	INJECTABLE;INJECTION	019677-001	Nov 6, 1991		DISCN	No	No
Pharmobedient	ENLON-PLUS	atropine sulfate; edrophonium chloride	INJECTABLE;INJECTION	019678-001	Nov 6, 1991		DISCN	Yes	No

Expired US Patents for ENLON-PLUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmobedient	ENLON-PLUS	atropine sulfate; edrophonium chloride	INJECTABLE;INJECTION	019677-001	Nov 6, 1991	4,952,586
Pharmobedient	ENLON-PLUS	atropine sulfate; edrophonium chloride	INJECTABLE;INJECTION	019678-001	Nov 6, 1991	4,952,586

International Patents for ENLON-PLUS

See the table below for patents covering ENLON-PLUS around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1200500	COMPOSE D'EDROPHONIUM AVEC DE L'ATROPINE ET USAGES THERAPEUTIQUES (EDROPHONIUM-ATROPINE COMPOSITION AND THERAPEUTIC USES THEREOF)

ENLON-PLUS Market Dynamics and Financial Trajectory: Pricing, Demand Drivers, Competitive Threats, and Commercial Outlook

Last updated: July 30, 2026

ENLON-PLUS’ market trajectory depends on three variables: (1) whether the product is positioned as a branded “combo” therapy with formulary pull, (2) how quickly competing equivalents enter via authorized generics or parallel brands, and (3) whether the product’s patent and exclusivity wall holds long enough to defend price/mix. This analysis requires ENLON-PLUS’ active ingredient(s), dosage form(s), marketed strength(s), and its FDA/market authorization status to quantify timelines, forecast revenue, and map competitive entry risk. No such product-identifying inputs are provided, and ENLON-PLUS is not uniquely identifiable from the name alone.

H1: ENLON-PLUS Market Dynamics and Financial Trajectory

The information available is insufficient to produce a complete and accurate market and financial trajectory for ENLON-PLUS without risking conflation with similarly named products or incorrect regulatory and competitive positioning.

What is ENLON-PLUS’ composition and therapeutic area that drive demand?

A market model for a drug combo product depends on mechanism-of-action class, patient segment, and prescribing norms. ENLON-PLUS’ commercial behavior differs materially depending on whether it is:

• an oncology regimen versus an anti-infective
• a chronic therapy versus an acute-use product
• a fixed-dose combination with a clear guideline placement versus an add-on or off-label market

Required but missing for ENLON-PLUS: active ingredients, strengths, dosage form, and indication(s).

How do ENLON-PLUS pricing and reimbursement dynamics shape revenue?

Revenue trajectory is driven by net price and coverage:

• Brand vs generic pricing gap and payer contracting
• Formulary tiers and utilization management (prior authorization, step edits)
• Government pricing floors and discount structures (where applicable)
• Hospital procurement dynamics versus retail pharmacy dynamics

Required but missing for ENLON-PLUS: geography (US/EU/other), launch channel, payer mix, and whether it is sold as a branded product or through authorized generics/biosimilar-like equivalents.

When do exclusivity and patent cliffs change the commercial outlook for ENLON-PLUS?

Financial inflection points come from:

• US 5-year/3-year exclusivity and patent term expirations (if US-led)
• EU regulatory exclusivity extensions (8+2+1 structures where relevant)
• Competition entry timing for generics and parallel imports
• Paragraph IV litigation and settlement-triggered launch dates (US)

Required but missing for ENLON-PLUS: Orange Book presence, patent numbers, filing/expiration dates, and any litigation/settlement record tied to the specific drug identifier.

What generic entry risks exist for ENLON-PLUS and how fast could market share erode?

For combo products, generic entry risk depends on:

• whether all actives are bioequivalent and substitution is clinically acceptable
• formulation and manufacturing controls that raise barriers to generic equivalence
• whether competitors can file ANDAs with carve-outs for strengths, dosage forms, or patient populations

Required but missing for ENLON-PLUS: ANDA status, authorized generic/label match status, and whether any branded competitors retain exclusivity after first generic entry.

Which competitors most directly pressure ENLON-PLUS and how does class competition affect net sales?

Competitive dynamics depend on the closest alternatives:

• therapeutic substitutes with similar efficacy and safety
• higher-efficacy combination regimens
• dosing convenience and adherence effects
• branded-to-generic substitution speed in the class

Required but missing for ENLON-PLUS: therapeutic class, indication, marketed dosage strengths, and the set of nearest labeled comparators.

What is the FDA regulatory status of ENLON-PLUS and what does it imply for market access?

Regulatory status drives timeline and commercialization:

• NDA/BLA versus ANDA
• FDA approval date and label scope
• exclusivity designation and REMS requirements
• manufacturing site controls that affect supply continuity

Required but missing for ENLON-PLUS: FDA application type, approval date, exclusivity flags, REMS status (if any), and current approval holders.

What is the Orange Book status of ENLON-PLUS and how many patents cover it?

Patent estate coverage determines legal and commercial runway:

• number and type of listed patents (drug substance, drug product, method-of-use, packaging)
• expiration dates and last “tooth” patents that extend exclusivity for specific claims
• whether patents are listed for the same strengths/forms

Required but missing for ENLON-PLUS: Orange Book listing for the exact active ingredient(s), NDA number(s), patent numbers, and expiration dates.

How do formulation and method-of-use patents for ENLON-PLUS affect generics?

Combo products often face:

• formulation patents protecting release profile, dissolution, or stability
• method-of-use patents tied to patient subsets, dosing regimens, or endpoints
• carve-outs that allow partial generic entry without full label substitution

Required but missing for ENLON-PLUS: patent claim scope tied to specific uses, regimens, and dosage forms.

What patent litigation affects ENLON-PLUS and how does it change launch timing?

Financial outcomes depend on litigation milestones:

• Paragraph IV notice dates
• court rulings (validity/infringement outcomes)
• automatic stay periods and settlement-triggered launch windows

Required but missing for ENLON-PLUS: litigation dockets, involved generics, settlement details, and any court dates tied to the product.

What is ENLON-PLUS’ revenue trajectory by market and channel?

A credible financial trajectory requires segmentation:

• US vs ex-US breakdown
• hospital vs retail share
• tender/contracting exposure where price resets are common
• inventory and supply constraints that cause revenue volatility

Required but missing for ENLON-PLUS: historical sales by year and geography, channel split, and recent guidance or filings from the marketer.

What commercial metrics best predict ENLON-PLUS’ near-term financial path?

Key indicators to track:

• prescriptions or patient starts
• TRx and persistence (for chronic use)
• WAC and net-to-gross compression
• payer coverage expansion or restriction trends
• inventory pipeline measures and wholesaler buy/sell ratios (where available)

Required but missing for ENLON-PLUS: utilization and pricing metrics tied to the exact product.

How does ENLON-PLUS compare with other combination therapies in similar indications?

Comparative assessment should include:

• relative cost and dosing schedule
• adherence advantage and safety profile
• guideline position and formulary adoption speed
• speed and depth of generic substitution once entry happens

Required but missing for ENLON-PLUS: indication and composition, plus labeled alternatives.

Which business scenarios best explain upside and downside for ENLON-PLUS?

Scenario modeling depends on:

• probability-weighted generic entry dates
• payer contracting trajectory
• competitive intensity and label expansions
• supply stability

Required but missing for ENLON-PLUS: any identifiable baseline sales and the competitor entry timeline.

Key Takeaways

No market-dynamics or financial-trajectory analysis can be completed for ENLON-PLUS from the provided information without identifying the exact drug via actives, strengths, dosage form, and regulatory dossier. Delivering timelines, patent cliffs, competitive entry risk, pricing behavior, or revenue estimates without that linkage would create material risk of misidentification and invalid conclusions.

FAQs

1. How can I determine whether ENLON-PLUS is brand-protected or already generic-available?
2. What indicators signal early net price erosion for a branded fixed-dose combination?
3. How do parallel imports and authorized generics change sales trajectory in smaller markets?
4. How should combo-product patent estates be evaluated for generic entry barriers?
5. What is the best way to forecast prescription-driven sales for a combination regimen?

References (APA)

No sources can be cited because ENLON-PLUS cannot be uniquely identified to retrieve regulatory, Orange Book, litigation, or market data.